Table 1.
Clinical-pathological characteristics of the study participants (N: 235)
| Characteristics | Number (N) and percentage (%) |
|---|---|
| Age (years) | N (%) |
| Mean (SD) | 60.3 (13.4) |
| Histology | |
| Intraductal carcinoma | 204 (86.8) |
| Lobular carcinoma | 14 (6.0) |
| Other | 9 (3.8) |
| Unknown | 8 (3.4) |
| pT stage | |
| pT1 | 131 (55.7) |
| pT2 | 104 (44.3) |
| pN stage | |
| pN0 | 141 (60.0) |
| pN1 | 83 (35.3) |
| Unknown | 11 (4.7) |
| Grading | |
| 1 | 16 (6.8) |
| 2 | 126 (53.6) |
| 3 | 64 (27.2) |
| Unknown | 29 (12.3) |
| Estrogen receptor status | |
| Positive | 186 (79.1) |
| Negative | 49 (20.9) |
| Progesterone receptor status | |
| Negative | 71 (30.2) |
| Positive | 164 (69.8) |
| HER2 status | |
| Positive | 39 (16.6) |
| Negative | 196 (83.4) |
| % Ki-67 | |
| ≤ 15 | 142 (60.4) |
| > 15 | 89 (37.9) |
| Unknown | 4 (1.7) |
| Molecular subtype | |
| Triple-negative | 30 (12.8) |
| Luminal A | 118 (50.2) |
| Luminal B | 69 (29.3) |
| HER2-enriched | 18 (7.7) |